See the DrugPatentWatch profile for methotrexate

Methotrexate is a medication commonly used to treat certain types of cancer, rheumatoid arthritis, and severe psoriasis [1]. It is a potent drug that can have various side effects, and one question that may arise is whether methotrexate can cause lasting kidney damage.

According to the information available, methotrexate can have adverse effects on the kidneys [1][2]. The drug can cause acute kidney injury, which is typically reversible [1]. However, there is some evidence suggesting that methotrexate may also lead to chronic kidney disease in rare cases [2].

A study published in the Journal of Clinical Rheumatology analyzed data from a large group of rheumatoid arthritis patients who were taking methotrexate [2]. The study found that long-term methotrexate use was associated with an increased risk of chronic kidney disease, even after adjusting for other factors that could affect kidney function [2].

It is important to note that the risk of kidney damage from methotrexate appears to be low, and the benefits of the medication often outweigh the risks for patients who need it [1]. Nonetheless, healthcare providers should monitor kidney function in patients taking methotrexate, particularly if they are taking high doses or have other risk factors for kidney disease [1].

In summary, methotrexate can cause kidney damage, although this is typically acute and reversible [1][2]. There is some evidence suggesting that long-term methotrexate use may increase the risk of chronic kidney disease, but the risk appears to be low [2]. Healthcare providers should monitor kidney function in patients taking methotrexate.

Sources:
[1] "Methotrexate." National Cancer Institute, 2021, <https://www.cancer.gov/about-cancer/treatment/drugs/methotrexate>.
[2] Radhakrishnan, J., et al. "Methotrexate and the Kidney: Risks and Recommendations for Monitoring." Journal of Clinical Rheumatology, vol. 21, no. 5, 2015, pp. 265-272., doi: 10.1097/RHU.0000000000000155.

(Note: The sources cited are independent of DrugPatentWatch.com)